Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 2
2006 4
2007 2
2008 7
2009 3
2011 8
2012 6
2013 9
2014 5
2015 6
2016 2
2017 5
2018 5
2019 7
2020 6
2021 1
2022 3
2023 4
2024 2
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Deferasirox for managing iron overload in people with thalassaemia.
Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ. Bollig C, et al. Cochrane Database Syst Rev. 2017 Aug 15;8(8):CD007476. doi: 10.1002/14651858.CD007476.pub3. Cochrane Database Syst Rev. 2017. PMID: 28809446 Free PMC article.
One study compared the combination of deferasirox and deferiprone to deferiprone in combination with deferoxamine. Three three-arm studies compared deferasirox to deferoxamine and deferiprone (two studies) or the combination of deferasirox and deferiprone to …
One study compared the combination of deferasirox and deferiprone to deferiprone in combination with deferoxamine. Three three-arm st …
Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis.
Qadah T. Qadah T. J Int Med Res. 2022 Dec;50(12):3000605221143290. doi: 10.1177/03000605221143290. J Int Med Res. 2022. PMID: 36562113 Free PMC article.
OBJECTIVES: To examine the efficacy of deferasirox (DFX) by comparison with deferoxamine (DFO) in managing iron overload in patients with sickle cell anaemia (SCA). ...
OBJECTIVES: To examine the efficacy of deferasirox (DFX) by comparison with deferoxamine (DFO) in managing iron overload in patients …
Deferasirox for managing iron overload in people with thalassaemia.
Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D. Meerpohl JJ, et al. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD007476. doi: 10.1002/14651858.CD007476.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2017 Aug 15;8:CD007476. doi: 10.1002/14651858.CD007476.pub3. PMID: 22336831 Updated.
However, a systematic review of the effectiveness and safety of the new oral chelator deferasirox in people with thalassaemia is needed. OBJECTIVES: To assess the effectiveness and safety of oral deferasirox in people with thalassaemia and secondary iron overload. . …
However, a systematic review of the effectiveness and safety of the new oral chelator deferasirox in people with thalassaemia is need …
Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
Dou H, Qin Y, Chen G, Zhao Y. Dou H, et al. Acta Haematol. 2019;141(1):32-42. doi: 10.1159/000494487. Epub 2018 Nov 30. Acta Haematol. 2019. PMID: 30504715
Deferasirox (DFX) has recently been used to treat thalassemia with iron overload; however, its long-term effectiveness and safety await multi-year studies. ...
Deferasirox (DFX) has recently been used to treat thalassemia with iron overload; however, its long-term effectiveness and safety awa …
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, Dickson R, Dundar Y, Greenhalgh J, Modell B, Olujohungbe A, Telfer P, Walley T. McLeod C, et al. Health Technol Assess. 2009 Jan;13(1):iii-iv, ix-xi, 1-121. doi: 10.3310/hta13010. Health Technol Assess. 2009. PMID: 19068191 Free article.
Because of the paucity of long-term data we developed a simple, short-term (1 year) model to assess the costs and benefits of deferasirox, deferiprone and DFO in patients with beta-TM and SCD from an NHS perspective. ...Furthermore, if deferiprone is proven to offer the sa …
Because of the paucity of long-term data we developed a simple, short-term (1 year) model to assess the costs and benefits of deferasirox …
No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.
Saleem A, Waqar E, Shuja SH, Naeem U, Moeed A, Rais H, Ahmed J. Saleem A, et al. Transfus Clin Biol. 2023 Feb;30(1):69-74. doi: 10.1016/j.tracli.2022.07.004. Epub 2022 Jul 22. Transfus Clin Biol. 2023. PMID: 35878782
OBJECTIVES: Iron overload is a common complication experienced by transfusion-dependent children with hemoglobin disorders. Chelators such as deferasirox (DFX) and deferiprone (DFP) are effective in overcoming this problem. We conducted this systematic review and meta-anal …
OBJECTIVES: Iron overload is a common complication experienced by transfusion-dependent children with hemoglobin disorders. Chelators such a …
Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study.
Sarocchi M, Li J, Li X, Wu D, Montaño Figueroa E, Rodriguez MG, Hou M, Finelli C, Shi HX, Xiao Z, Oliva EN, Gercheva Kyuchukova L, Drummond M, Symeonidis A, Velazquez EJ, Rivoli G, Izquierdo M, Kolekar Y, Spallarossa P, Angelucci E. Sarocchi M, et al. Br J Haematol. 2024 May;204(5):2049-2056. doi: 10.1111/bjh.19316. Epub 2024 Feb 11. Br J Haematol. 2024. PMID: 38343073 Clinical Trial.
Patients receiving deferasirox experienced a significant decrease in the composite risk of hospitalisation for congestive heart failure (CHF) or worsening of cardiac function (HR = 0.23; 95% CI: 0.05, 0.99; nominal p = 0.0322) versus placebo. ...These results support the e …
Patients receiving deferasirox experienced a significant decrease in the composite risk of hospitalisation for congestive heart failu …
Deferasirox does not induce QT/QTc-prolongation in healthy subjects.
Sechaud R, Dumortier T, Balez S. Sechaud R, et al. Int J Clin Pharmacol Ther. 2009 May;47(5):321-7. doi: 10.5414/cpp47321. Int J Clin Pharmacol Ther. 2009. PMID: 19473594 Clinical Trial.
Study participants were randomized to four treatments arms: deferasirox 20 mg/kg (n = 46), deferasirox 40 mg/kg (n = 46), placebo (n = 46) or moxifloxacin 400 mg (n = 44). ...RESULTS: Deferasirox 20 and 40 mg/kg were noninferior to placebo with respect to the …
Study participants were randomized to four treatments arms: deferasirox 20 mg/kg (n = 46), deferasirox 40 mg/kg (n = 46), plac …
Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study.
Taher AT, Wali Y, Cruz MC, Charoenkwan P, Aydinok Y, Werner O, Govindaraju S, Romen F, Viprakasit V. Taher AT, et al. Haematologica. 2024 May 1;109(5):1413-1425. doi: 10.3324/haematol.2023.283133. Haematologica. 2024. PMID: 37855069 Free PMC article. Clinical Trial.
Identifier: NCT02435212), a randomized, open-label, multicenter, phase II study evaluated the compliance, clinical benefits, and safety of deferasirox granules and dispersible tablets (DT) in pediatric patients with iron overload. ...In iron chelation therapy-naive patient …
Identifier: NCT02435212), a randomized, open-label, multicenter, phase II study evaluated the compliance, clinical benefits, and safety of …
Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
Shashaty G, Frankewich R, Chakraborti T, Choudary J, Al-Fayoumi S, Kacuba A, Castillo S, Robie-Suh K, Rieves D, Weiss K, Pazdur R. Shashaty G, et al. Oncology (Williston Park). 2006 Dec;20(14):1799-1806, 1811; discussion 1811-13, 1817. Oncology (Williston Park). 2006. PMID: 17263129 Free article. Clinical Trial.
Deferasirox was associated with serum creatinine increases in approximately a third of patients. ...Other data provided supportive evidence of deferasirox safety and efficacy. CONCLUSIONS: The FDA granted deferasirox accelerated approval on November 2, 2005, …
Deferasirox was associated with serum creatinine increases in approximately a third of patients. ...Other data provided supportive ev …
81 results